Effect of immobilized hyaluronidase and subtilisin enzymes on the ultrastructure of human conjunctival epithelial cells

The use of enzyme preparations is a traditional trend in various fields of medicine. The usage of immobilized enzymes hyaluronidase (IG) and subtilisin (IS) seems to be very promising for the treatment of damage to the ocular surface. The aim of the study was to establish the nature of changes in the ultrastructural organization  of human conjunctival epithelium under the influence of  immobilized hyaluronidase and subtilisin in vitro. Material and methods. In the experiment, a culture of normal cells of the human conjunctiva Chanqconjunctiva, clone 1–5 C-4, was seeded in 96well plates in the amount of 2 × 10⁴ cells/well, after 24 h the medium was removed, Eagle’s medium MEM and fetal calf serum were added and cells were cultured for another 48 h. 5 experimental groups were formed: group 1 – without drugs (except for the composition of the incubation scheme), groups 2 and 3 – with IS at a concentration of 37 and 150 U/ml, respectively, groups 4 and 5 – with IG at a concentration of 37 and 150 U/ml, respectively. After preparation of cell preparations under a JEM 1400 electron microscope (Japan), ultrathin sections of 70–100 nm were studied at ×1000 magnification. Results. The article presents the results of electron microscopy of a culture of normal cells of the human conjunctiva in 5 experimental groups of cells with a description of changes in cytoarchitectonics under the influence of IG and IS. Conclusions. The introduction of immobilized enzymes into human conjunctival cell culture at a low dose (37 U/ml) affects the organization of cells without cytotoxic effects, while increasing the dose directly correlates with the occurrence of a cytotoxic effect.

1. Cioni P., Gabellieri E., Campanini B., Bettati S., Raboni S. Use of exogenous enzymes in human therapy: approved drugs and potential applications. Curr. Med. Chem. 2022;29(3):411–452. doi: 10.2174/0929867328666210713094722

2. Hennigan J.N., Lynch M.D. The past, present, and future of enzyme-based therapies. Drug Discov. Today. 2022;27(1):117–133. doi: 10.1016/j.drudis.2021.09.004

3. Yari M., Ghoshoon M.B., Vakili B., Ghasemi Y. Therapeutic enzymes: applications and approaches to pharmacological improvement. Curr. Pharm. Biotechnol. 2017;18(7):531–540. doi: 10.2174/1389201018666170808150742

4. Sharma D.S.C., Lahiri M.A. Use of hyaluronidase in plastic surgery: A review. J. Plast. Reconstr. Aesthet. Surg. 2021;74(7):1610–1614. doi: 10.1016/j.bjps.2021.03.125

5. Buhren B.A., Schrumpf H., Gorges K., Reiners O., Bölke E., Fischer J.W., Homey B., Gerber P.A. Dose- and time-dependent effects of hyaluronidase on structural cells and the extracellular matrix of the skin. Eur. J. Med. Res. 2020;25(1):60. doi: 10.1186/s40001-020-00460-z

6. Weber G.C., Buhren B.A., Schrumpf H., Wohlrab J., Gerber P.A. Clinical applications of hyaluronidase. Adv. Exp. Med. Biol. 2019;1148:255–277. doi: 10.1007/978-981-13-7709-9_12

7. Mishenina S.V., Baikalov G.I., Baikalova N.E., Makarov V.K., Madonov P.G. A rationale for application of immobilized subtilisines for target therapy of venous thrombosis. J. Sib. Med. Sci. 2020;(1):76–88. [In Russian]. doi: 10.31549/2542-1174-2020-1-76-88

8. Madonov P.G., Momot A.P., Mamaev A.N., Roitman E.V., Mishenina S.V. Non-plasmin fibrinolysis with immobilized subtilisins. Tromboz, gemostaz i reologiya = Thrombosis, Hemostasis and Rheology. 2019;3(79):24–32. [In Russian]. doi.org/10.25555/THR.2019.3.0886

9. Emedova T.A., Makarov K.Yu., Madonov P.G., Sokolova T.M., Aidagulova S.V., Marinkin I.O. Positive effect of immobilized subtilisins at the treatment of estrogen-induced chronic venous insufficiency. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2017;37(4): 47–52. [In Russian].

10. Azrin N.A.M., Ali M.S.M., Rahman R.N.Z.R.A., Oslan S.N., Noor N.D.M. Versatility of subtilisin: A review on structure, characteristics, and applications. Biotechnol. Appl. Biochem. 2022. doi: 10.1002/bab.2309

11. Weng Y., Yao J., Sparks S., Wang K.Y. Nattokinase: an oral antithrombotic agent for the prevention of cardiovascular disease. Int. J. Mol. Sci. 2017;18(3):523. doi: 10.3390/ijms18030523

12. Yuan L., Liangqi C., Xiyu T., Jinyao L. Biotechnology, bioengineering and applications of bacillus nattokinase. Biomolecules. 2022;12(7):980. doi: 10.3390/biom12070980

13. Hodis H.N., Mack W.J., Meiselman H.J., Kalra V., Liebman H., Hwang-Levine J., Dustin L., Kono N., Mert M., Wenby R.B., … Whitfield L. Nat-tokinase atherothrombotic prevention study: A randomized controlled trial. Clin. Hemorheol. Microcirc. 2021;78(4):339–353. doi: 10.3233/CH-211147

14. de la Fuente M., Lombardero L., Gómez-González A., Solari C., Angulo-Barturen I., Acera A., Vecino E., Astigarraga E., Barreda-Gómez G. Enzyme therapy: current challenges and future perspectives. Int. J. Mol. Sci. 2021;22(17):9181. doi: 10.3390/ijms22179181

15. Madonov P.G., Ershov K.I., Dubrovin A.V., Zapolotsky E.N., Miroshnikov P.N., Shilova M.A., Kinsht D.N. Electron-beam modification of preparations of the albuminous nature for improvement of their pharmacological properties. Meditsina i obrazovanie v Sibiri = Medicine and Education in Siberia. 2013;(4):40–52. [In Russian].

16. Nazarenko K.A., Khoroshikh Yu.I., Zapuskalov I.V. Enzyme therapy in ophthalmology. Vestnik oftal’mologii = The Russian Annals of Ophthalmology. 2006;122(3):36–42. [In Russian].

17. Madonov P.G., Mishenina S.V., Kinsht D.N., Kikhtenko N.V. Chemical and pharmacological properties of subtilisins. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2016;36(3):13–22. [In Russian].

18. Madonov P.G., Mishenina S.V., Kinsht D.N., Kikhtenko N.V. Targeted pharmacodynamics of subtilisins. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2016;36(4):15–24. [In Russian].

19. Dygai A.M., Pershina O.V., Krupin V.A., Ermolaeva L.A., Ermakova N.N., Shilova M.A., Madonov P.G., Kinsht D.N., Skurikhin E.G. Study of the antifibrotic activity of modified and native hyaluronidase at pulmonary fibrosis. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2017;37(4):5–10. [In Russian].

20. Skurikhin E., Madonov P., Pershina O., Ermakova N., Pakhomova A., Widera D., Pan E., Zhukova M., Sandrikina L., Artamonov A., Dygai A. Micellar hyaluronidase and spiperone as a potential treatment for pulmonary fibrosis. Int. J. Mol. Sci. 2021;22:5599. doi: 10.3390/ijms22115599

21. Şapte E., Costea C.F., Cărăuleanu A., Dancă C., Dumitrescu G.F., Dimitriu G., Chihaia M.A., Buzdugă C.M., Cucu A., Turliucet M.D. Histological, immunohistochemical and clinical considerations on amniotic membrane transplant for ocular surface reconstruction. Rom. J. Morphol. Embryol. 2017;58:363–369.

22. Dua H.S., Faraj L.A., Said D.G., Gray T., Lowe J. Human corneal anatomy redefined: A novel pre-Descemet’s layer (Dua’s Layer). Ophthalmology. 2013;120(9):1778–1785. doi: 10.1016/j.ophtha.2013.01.018